The Valley Desk

Clinical trial reportAnnals of oncology : official journal of the European Society for Medical OncologyPublished

Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Annals of oncology : official journal of the European Society for Medical Oncology
Published
Subject terms
Humans; Breast Neoplasms; Neoplasm Recurrence, Local; Estradiol; Inhibins; Follicle Stimulating Hormone; Receptors, Estrogen; Receptors, Progesterone; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Chemotherapy, Adjuvant; Adult
PubMed ID
42613139
PubMed Central ID
PMC13488494
Added to directory
Source checked

Report a correction or request removal